218 related articles for article (PubMed ID: 38172228)
1. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC.
Lu J; Ji X; Liu X; Jiang Y; Li G; Fang P; Li W; Zuo A; Guo Z; Yang S; Ji Y; Lu D
Sci Rep; 2024 Jan; 14(1):446. PubMed ID: 38172228
[TBL] [Abstract][Full Text] [Related]
2. Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis.
Fan Y; Wang X; Yang C; Chen H; Wang H; Wang X; Hou S; Wang L; Luo Y; Sha X; Yang H; Yu T; Jiang X
J Magn Reson Imaging; 2023 Dec; 58(6):1838-1847. PubMed ID: 37144750
[TBL] [Abstract][Full Text] [Related]
3. Preoperative MRI-Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR-TKI Treatment in NSCLC.
Fan Y; He L; Yang H; Wang Y; Su J; Hou S; Luo Y; Jiang X
J Magn Reson Imaging; 2023 Jun; 57(6):1778-1787. PubMed ID: 36165534
[TBL] [Abstract][Full Text] [Related]
4. CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.
Li Y; Lv X; Wang Y; Xu Z; Lv Y; Hou D
Eur Radiol Exp; 2023 Nov; 7(1):64. PubMed ID: 37914925
[TBL] [Abstract][Full Text] [Related]
5. Combined radiomics of primary tumour and bone metastasis improve the prediction of EGFR mutation status and response to EGFR-TKI therapy for NSCLC.
Cheng Y; Wang H; Yuan W; Wang H; Zhu Y; Chen H; Jiang W
Phys Med; 2023 Dec; 116():103177. PubMed ID: 38000098
[TBL] [Abstract][Full Text] [Related]
6. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
[TBL] [Abstract][Full Text] [Related]
7. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Qu J; Zhang T; Zhang X; Zhang W; Li Y; Gong Q; Yao L; Lui S
Clin Radiol; 2024 Apr; 79(4):e582-e591. PubMed ID: 38310058
[TBL] [Abstract][Full Text] [Related]
8. Using contrast-enhanced CT and non-contrast-enhanced CT to predict EGFR mutation status in NSCLC patients-a radiomics nomogram analysis.
Yang X; Liu M; Ren Y; Chen H; Yu P; Wang S; Zhang R; Dai H; Wang C
Eur Radiol; 2022 Apr; 32(4):2693-2703. PubMed ID: 34807270
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
10. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
12. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC.
Fan Y; Wang X; Dong Y; Cui E; Wang H; Sun X; Su J; Luo Y; Yu T; Jiang X
Eur Radiol; 2023 Nov; 33(11):7902-7912. PubMed ID: 37142868
[TBL] [Abstract][Full Text] [Related]
13. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
14. A Radiomics-clinical Nomogram based on CT Radiomics to Predict Acquired T790M Mutation Status in Non-small Cell Lung Cancer Patients.
Xiong W; Yu X; Zhou T; Huang H; Zhao Z; Wang T
Curr Med Imaging; 2024 Mar; ():. PubMed ID: 38523520
[TBL] [Abstract][Full Text] [Related]
15. Radiomic Detection of EGFR Mutations in NSCLC.
Rossi G; Barabino E; Fedeli A; Ficarra G; Coco S; Russo A; Adamo V; Buemi F; Zullo L; Dono M; De Luca G; Longo L; Dal Bello MG; Tagliamento M; Alama A; Cittadini G; Pronzato P; Genova C
Cancer Res; 2021 Feb; 81(3):724-731. PubMed ID: 33148663
[TBL] [Abstract][Full Text] [Related]
16. Machine Learning-Based Radiomics for Prediction of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma.
Lu J; Ji X; Wang L; Jiang Y; Liu X; Ma Z; Ning Y; Dong J; Peng H; Sun F; Guo Z; Ji Y; Xing J; Lu Y; Lu D
Dis Markers; 2022; 2022():2056837. PubMed ID: 35578691
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
18. Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?
Yang X; Fang C; Li C; Gong M; Yi X; Lin H; Li K; Yu X
Front Oncol; 2022; 12():904983. PubMed ID: 35875167
[TBL] [Abstract][Full Text] [Related]
19. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
20. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
